KIRhub 2.0
Sign inResearch Use Only

MAPKAPK2

Sign in to save this workspace

UniProt P49137 · PDB · AlphaFold · Substrate: Glycogen Synthase-derived peptide · Clone: ful length

Top inhibitors

#DrugInhibitionResidualKISSGini
1Asciminib15.3%84.7%100.000.602
2Acalabrutinib13.3%86.7%99.500.670
3Paxalisib12.2%87.8%99.750.609
4Lapatinib11.5%88.5%99.250.616
5Neratinib11.5%88.5%93.180.597
6Ruxolitinib11.3%88.7%98.250.592
7Ponatinib10.7%89.3%78.230.534
8Gedatolisib10.4%89.6%99.750.611
9Defactinib10.2%89.8%92.680.450
10Brigatinib10.0%90.0%82.960.513
11Pirtobrutinib9.8%90.2%99.490.656
12Crizotinib9.8%90.2%91.390.581
13Tenalisib9.4%90.6%97.980.702
14Vemurafenib9.3%90.7%96.490.598
15Idelalisib8.7%91.3%100.000.701
16Duvelisib8.5%91.5%100.000.716
17Dacomitinib7.8%92.2%97.990.664
18Abrocitinib7.4%92.6%99.500.581
19Sorafenib7.3%92.7%96.720.776
20Avapritinib6.9%93.1%97.730.644

Paralog block

No paralog group registered for this kinase.

EMT expression

  • Mesenchymal log2(TPM+1): 5.51
  • Epithelial log2(TPM+1): 4.85
  • Fold change: 0.66
  • Status: No significant change

Selectivity landscape vs inhibition on MAPKAPK2

Each point is one of the 92 approved drugs; color = inhibition % on MAPKAPK2.

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…